InventisBio (Shanghai) Co. Ltd. Is an innovative drug development company with a global vision based in China, focusing on oncology, metabolic diseases and other major disease areas. The company aims to address unmet clinical needs and is committed to developing innovative drugs with independent intellectual property rights in China that serves the world. It consistently provides patients with safer, more effective and affordable treatment solutions. Inventis Bio has clinical studies in China, the United States, Australia, Taiwan, Korea, Japan and other countries. Emphasis on R&D investment has enabled Inventis Bio to gain a fast growth in product pipeline and clinical study. 50+ operation teams are still in a rapid expansion phase. Driven by the complex environment, the integration of data and the improvement of personnel effectiveness become essential which leads to the integration of Taimei CTMS system with Rave EDC data.